Compare GIFT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GIFT | TVGN |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0M | 21.3M |
| IPO Year | 2019 | 2021 |
| Metric | GIFT | TVGN |
|---|---|---|
| Price | $0.62 | $6.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 231.7K | 4.3K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $83,181,716.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.14 |
| 52 Week High | $1.29 | $39.00 |
| Indicator | GIFT | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 43.43 |
| Support Level | $0.58 | $6.22 |
| Resistance Level | $0.70 | $7.72 |
| Average True Range (ATR) | 0.11 | 0.57 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 65.40 | 34.73 |
Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.